Table 2.
Identified differential metabolites between colorectal cancer and adjacent normal controls from each of tissue samples
| Samples from Shanghai | Samples from Hangzhou |
Samples from Beijing |
Samples from City of Hope |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|||||||
| No. | Metabolite name | VIP | FCa,c | Pb,c | FCa,c | Pb,c | FCa,c | Pb,c | FCa,c | Pb,c |
| 1 | Kynurenined | 2.55 | 5.50 | 6.49E–14 | 2.64 | 1.68E–05 | 4.31 | 2.34E–05 | 2.20 | 1.92E–03 |
| 2 | β-Alanined | 2.48 | 5.02 | 3.51E–13 | 4.56 | 9.09E–11 | 6.01 | 3.23E–06 | 2.79 | 1.00E–03 |
| 3 | Glutamated | 2.25 | 1.88 | 3.54E–10 | 1.92 | 8.68E–08 | 1.87 | 4.14E–04 | 1.53 | 8.06E–03 |
| 4 | Cysteined | 2.14 | 2.41 | 8.02E–10 | 1.87 | 3.54E–04 | 1.33 | 4.79E–02 | 1.92 | 1.40E–02 |
| 5 | 2-Aminobutyrated | 2.13 | 1.81 | 3.05E–09 | 1.49 | 7.97E–03 | 1.58 | 4.17E–02 | 1.49 | 4.45E–02 |
| 6 | Palmitoleated | 1.90 | 3.09 | 3.03E–08 | 2.25 | 2.98E–04 | 2.70 | 1.21E–02 | 2.22 | 9.59E–03 |
| 7 | 5-Oxoprolined | 1.96 | 1.76 | 5.89E–08 | 1.45 | 1.88E–03 | 2.13 | 2.16E–02 | 1.47 | 2.35E–02 |
| 8 | Aspartated | 1.92 | 1.80 | 1.17E–07 | 1.58 | 1.95E–03 | 1.49 | 2.17E–02 | 1.70 | 1.65E–02 |
| 9 | Hypoxanthined | 1.84 | 1.71 | 5.16E–07 | 1.36 | 1.28E–03 | 2.12 | 6.12E–06 | 1.38 | 3.80E–02 |
| 10 | Lactated | 1.87 | 1.68 | 5.89E–07 | 1.49 | 4.34E–07 | 1.45 | 1.95E–04 | 1.55 | 2.21E–02 |
| 11 | Myristated | 1.56 | 1.59 | 6.54E–05 | 2.06 | 3.11E–06 | 2.15 | 8.45E–03 | 1.72 | 3.81E–02 |
| 12 | Glycerold | 1.36 | 1.48 | 3.77E–04 | 1.37 | 7.10E–03 | 1.28 | 3.06E–02 | 1.57 | 3.76E–02 |
| 13 | Uracild | 1.36 | 1.39 | 4.59E–04 | 1.47 | 4.59E–04 | 2.37 | 2.77E–03 | 1.58 | 4.29E–02 |
| 14 | Putrescined | 1.21 | 3.57 | 4.61E–04 | 1.48 | 4.84E–02 | 4.46 | 4.57E–03 | 2.78 | 4.94E–02 |
| 15 | Myo-inositold | 1.10 | −1.29 | 8.39E–03 | −1.33 | 3.78E–04 | −1.66 | 4.54E–07 | −1.49 | 1.96E–02 |
| 16 | Hypotaurine | 2.32 | 4.04 | 1.09E–11 | 2.59 | 2.10E–05 | 3.84 | 2.00E–05 | / | / |
| 17 | Spermidine | 1.37 | 1.89 | 1.02E–04 | 1.70 | 1.91E–05 | 2.34 | 2.44E–06 | / | / |
| 18 | Homocysteined | 1.73 | 1.79 | 1.84E–06 | 1.45 | 3.83E–03 | 2.33 | 8.77E–03 | / | / |
| 19 | 4-Aminobutyrate | 1.27 | 2.18 | 2.97E–04 | 1.35 | 5.14E–03 | 2.27 | 6.06E–03 | / | / |
| 20 | Asparagined | 1.33 | 1.47 | 4.40E–04 | 1.36 | 5.14E–03 | 1.96 | 1.86E–02 | / | / |
| 21 | Glycerated | 1.12 | −1.76 | 1.38E–02 | −2.00 | 1.90E–02 | / | / | −1.43 | 1.31E–02 |
| 22 | Nicotinamide | 1.39 | 1.56 | 2.54E–04 | / | / | 1.53 | 2.18E–02 | 1.61 | 5.39E–02 |
| 23 | AMPd | 1.46 | 2.78 | 4.66E–05 | 2.83 | 7.59E–05 | / | / | / | / |
| 24 | Ascorbated | 1.06 | 2.59 | 3.34E–03 | 1.43 | 2.07E–02 | / | / | / | / |
| 25 | Glucosed | 1.09 | −1.51 | 6.50E–03 | −2.37 | 1.01E–06 | / | / | / | / |
| 26 | Xylose | 1.16 | −1.63 | 1.61E–02 | −2.15 | 4.40E–02 | / | / | / | / |
| 27 | Glycined | 1.64 | 1.62 | 7.49E–06 | / | / | 1.53 | 1.22E–02 | / | / |
| 28 | Glyceraldehyded | 1.02 | 1.39 | 7.19E–03 | / | / | 1.37 | 4.15E–02 | / | / |
| 29 | Ornithined | 1.07 | 1.39 | 9.49E–03 | / | / | 2.28 | 1.91E–02 | / | / |
| 30 | Phosphate | 1.64 | 1.53 | 5.84E–06 | / | / | / | / | / | / |
| 31 | Laurated | 1.59 | 1.49 | 1.49E–05 | / | / | / | / | / | / |
| 32 | Galactose | 1.54 | 2.17 | 1.80E–05 | / | / | / | / | / | / |
| 33 | 3-Methy-3-hydrpoxybutyrate | 1.58 | 1.54 | 3.97E–05 | / | / | / | / | / | / |
| 34 | Methioninamide | 1.44 | 1.70 | 7.16E–05 | / | / | / | / | / | / |
| 35 | 2-Aminoadipate | 1.19 | 1.45 | 8.04E–04 | / | / | / | / | / | / |
Abbreviation: AMP, adenosine-50-monophosphate.
a
FC (fold change) with a positive value indicates a relatively higher level in tumor tissue, whereas a negative value means a relatively lower expression level as compared with the adjacent normal tissues.
b
P values are calculated from the Student t test.
c
Metabolites marked with/means these metabolites have a P value higher than 0.05 in the corresponding batch of samples.
d
The identification of these metabolites were confirmed with our standard compounds.